Inovio Shares Triple After FDA Grants Accelerated Approval for Voceryq

Shares of Inovio Pharmaceuticals surged past the $2 mark in after-hours trading following the Food and Drug Administration’s decision to grant accelerated approval to Voceryq. The treatment is designed to decrease the frequency of invasive surgeries for adults suffering from recurrent respiratory papillomatosis, a rare and persistent condition.

October 31, 2026, 02:22 AM 296 0

The drug, formerly tracked under the development name INO-3107, represents a significant regulatory milestone for the company. Following the announcement, investor confidence spiked, sending the stock price up to $2.17.

Management expects to begin the logistics of ordering and shipping within 60 days. While immediate availability is slated for the coming months, the company has scheduled the full-scale commercial launch for the first quarter of 2027.

When reusing this material a link to Money Talk is required.